(CRSP) Crispr Therapeutics - Ratings and Ratios
Exchange: NASDAQ • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: CH0334081137
CRSP: Gene, Editing, Therapies, Cancer, Diabetes, Stem, Cells
CRISPR Therapeutics AG, a pioneer in gene editing, is at the forefront of developing innovative gene-based therapies for severe human diseases. Their proprietary CRISPR/Cas9 platform enables precise modifications to genomic DNA, offering a transformative approach to treating genetic disorders. The companys diverse pipeline spans hemoglobinopathies, immune-oncology, autoimmune diseases, and type 1 diabetes, showcasing its broad therapeutic reach.
Their lead candidate, CASGEVY, exemplifies this innovation—an ex vivo CRISPR/Cas9 gene-edited cell therapy designed for transfusion-dependent beta-thalassemia and severe sickle cell disease. By editing hematopoietic stem cells to boost fetal hemoglobin production, CASGEVY addresses the root cause of these debilitating conditions, offering hope for patients seeking durable relief.
Complementing their ex vivo therapies, CRISPR Therapeutics is advancing an impressive in vivo pipeline. Programs like CTX310 and CTX320 target cardiovascular diseases by disrupting specific proteins, demonstrating their strategic approach to tackling complex conditions. Additionally, their allogeneic stem cell-derived product, VCTX211, aims to revolutionize type 1 diabetes treatment, highlighting their commitment to cutting-edge solutions.
The companys strategic collaborations with industry leaders such as Vertex Pharmaceuticals underscore its collaborative ethos, enhancing their ability to bring groundbreaking therapies to market. With a robust portfolio and a strong financial position, CRISPR Therapeutics AG is well-positioned to lead in the biotechnology sector, supported by a market cap exceeding $3.3 billion and forward P/E of 23.36, reflecting investor confidence in their growth potential.
Additional Sources for CRSP Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CRSP Stock Overview
| Market Cap in USD | 4,326m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2016-10-19 |
CRSP Stock Ratings
| Growth 5y | -38.6% |
| Fundamental | -37.9% |
| Dividend | 0.0% |
| Rel. Strength Industry | -41.5 |
| Analysts | 3.79/5 |
| Fair Price Momentum | 36.75 USD |
| Fair Price DCF | - |
CRSP Dividends
No Dividends PaidCRSP Growth Ratios
| Growth Correlation 3m | -33.7% |
| Growth Correlation 12m | -86% |
| Growth Correlation 5y | -58.7% |
| CAGR 5y | -1.61% |
| CAGR/Max DD 5y | -0.02 |
| Sharpe Ratio 12m | -1.01 |
| Alpha | -78.70 |
| Beta | 1.94 |
| Volatility | 81.43% |
| Current Volume | 2674.7k |
| Average Volume 20d | 2684.2k |
As of February 22, 2025, the stock is trading at USD 47.91 with a total of 2,674,673 shares traded.
Over the past week, the price has changed by -3.64%, over one month by +15.42%, over three months by +3.50% and over the past year by -41.86%.
Probably not. Based on ValueRay Fundamental Analyses, Crispr Therapeutics (NASDAQ:CRSP) is currently (February 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -37.88 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CRSP as of February 2025 is 36.75. This means that CRSP is currently overvalued and has a potential downside of -23.29%.
Crispr Therapeutics has received a consensus analysts rating of 3.79. Therefor, it is recommend to hold CRSP.
- Strong Buy: 11
- Buy: 4
- Hold: 11
- Sell: 0
- Strong Sell: 2
According to ValueRays Forecast Model, CRSP Crispr Therapeutics will be worth about 44.1 in February 2026. The stock is currently trading at 47.91. This means that the stock has a potential downside of -7.95%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 83.6 | 74.5% |
| Analysts Target Price | 84.1 | 75.5% |
| ValueRay Target Price | 44.1 | -8% |